Clinical Trial Update: Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating DCVAC/OvCa plus standard of care in relapsed platinum-resistant ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• DCVAC/OvCa

Snippet

Sponsor: SOTIO a.s. | Conditions: Epithelial Ovarian Carcinoma | Phase 2 | Status: TERMINATED